Ronald Milam, MD
Retina Specialist · Charlotte, NCNPI 1205256724
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.5%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Genentech USA, Inc. at 41.9% of the total. Reporting peaked in 2020 at $4,458 and has fallen 92.7% since, to $325 in 2025.
Across 60 payments — averaging $135.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$3K
- Regeneron$2K
- Novartis$1K
- Regeneron Healthcare Solutions, Inc.$270
- AbbVie$269
- Alimera Sciences, Inc.$137
- plus $502 from 9 others
Across 2 payments — averaging $175.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$352
What the payments were for
- Consulting fees$4,35354%
- Speaking & faculty fees$1041%
- Travel & lodging$2,21027%
- Food & beverage$1,46618%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 6 | $3,410 |
| Regeneron | 8 | $2,422 |
| Novartis | 2 | $1,123 |
| Regeneron Healthcare Solutions, Inc. | 7 | $270 |
| AbbVie(2 entities) | 13 | $269 |
| Alimera Sciences, Inc. | 6 | $137 |
| Apellis Pharmaceuticals, Inc. | 6 | $123 |
| Notal Vision, Inc. | 2 | $120 |
| Astellas Pharma US Inc | 3 | $79 |
| Harrow Eye, LLC | 1 | $54 |
| ANI Pharmaceuticals, Inc. | 2 | $52 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Eyepoint US, Inc. | 1 | $18 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,133 in reported general payments places this provider in the 65th percentile of 34 retina specialist providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 148 | $6,872 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 60 | $884 |
| Ciprofloxacin Hcl | 77 | $845 |
| Brimonidine Tartrate | 20 | $793 |
| Latanoprost | 66 | $455 |
| Ketorolac Tromethamine | 17 | $336 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Charlotte
- James HeromanCharlotte$434
- Eleonora LadDurham$331K
- Daniel BennettRaleigh$126K
- Michael AllinghamDurham$63K
- Raynor CaseyRaleigh$34K
- Sachin MudvariRaleigh$33K
- John ThordsenRaleigh$33K
- John DennyRaleigh$31K
- William BridgesAsheville$13K
- Rebecca ManningRaleigh$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.